Medidata launches new AI solution to modernize the data experience in clinical trials

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions for the life sciences industry, today announced the launch of Medidata Clinical Data Studio. This unified platform is designed to unlock the full potential of clinical research data.

This groundbreaking technology offers stakeholders enhanced control over data quality and accelerates the delivery of safer trials to patients.

Revolutionising Clinical Trials with Unified Platforms and AI-Powered Insights:

Built on the industry’s only unified platform, Clinical Data Studio integrates data from both Medidata and non-Medidata sources, streamlining decision-making throughout the entire clinical trial process. It delivers comprehensive data and risk strategies that connect patients, sites, and sponsors. Leveraging AI, study teams can more effectively identify potential data issues and safety signals, leading to a more accurate understanding of patient health.

This approach addresses the challenges of siloed data systems, enabling data review and reconciliation up to 80 percent faster. Clinical Data Studio provides a holistic workspace for data integration, transformation, and management, featuring AI-assisted data reconciliation, anomaly detection, self-serve data listings, robust risk-based quality management, and tools to implement comprehensive data and risk strategies supported by workflows and visualisations.

Medidata drives smarter treatments and healthier outcomes through digital solutions that support clinical trials. Celebrating 25 years of technological innovation across more than 33,000 trials and 10 million patients, Medidata offers unparalleled expertise, analytics-driven insights, and the largest patient-level historical clinical trial data set in the world.

"Clinical Data Studio unlocks the broad ecosystem of clinical data. Powered by embedded AI, we democratise data access and reveal the signals, risks, and insights that matter most. This accelerates trial execution and creates rich data for new discoveries," said Tom Doyle, chief technology officer at Medidata.

Click here to read the original news story.